






FIG. 1














FIG. 4




FIG. 5A




FIG. 5B





FIG. 6







FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 8E




FIG. 8F




FIG. 9

anti-mouse IgM detection of mouse anti-KLH
in sera collected at termination (study day 19)
(OD at 1:1000 dilution)




FIG. 10

anti-mouse IgG1 detection of mouse anti-KLH
in serum collected at termination (study day 19)
(OD at 1:1000 dilution)




FIG. 11




FIG. 12A




FIG. 12B




FIG. 12C






FIG. 12D



- 1 CTLA4 186-GSG4S - Fc - (G4S)4 - BCMA 406
- 2 CTLA4 186 - GSG4S - Fc - (G4S)4 - TACI 541
- 3 CTLA4 WT ECD 1 - GSG4S - Fc - (G4S)4 - BCMA 406
- 4 CTLA4 WT ECD 1 - GSG4S - Fc - (G4S)4 - TACI 541



- 1 CTLA4 186- GSG4S - Fc
- (G4S)4 - BCMA 406
- 2 CTLA4 186 - GSG4S - Fc
- (G4S)4 - TACI 541
- 3 CTLA4 WT ECD 1 - GSG4S
- Fc - (G4S)4 - BCMA 406
- 4 CTLA4 WT ECD 1 - GSG4S
- Fc - (G4S)4 - TACI 541

FIG. 13A




FIG. 13B




FIG. 13C





FIG. 13D



- 1 CTLA4 186- GSG4S - Fc
- (G4S)4 - BCMA 406
- 2 CTLA4 186 - GSG4S - Fc
- (G4S)4 - TACI 541
- 3 CTLA4 WT ECD 1 - GSG4S
- Fc (G4S)4 - BCMA 406
- 4 CTLA4 WT ECD 1 - GSG4S
- Fc - (G4S)4 - TACI 541

FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 14F




FIG. 14G




FIG. 14H




FIG. 14I





FIG. 15**Soluble BCMA-Fc**

FIG. 16




FIG. 17A

TACI 709	MSGIGRSRRGGRSRVDQEERFPQGLWTGVAMRSCPEEQYWDPELLGTCTMCKTICNHQSQR	60
TACI 528	-----	0
TACI 709	TCAAFCRSLSCRKEQGKFFYDHLRLRDCISCSICGQHPKQCA YFCENKLRSPVNLPPELRR	120
TACI 528	-----SLSCRKEQGKFFYDHLRLRDCISCSICGQHPKQCA YFCENKLR-----	43

TACI 709	QRSGEVENNSDMSGRYQGLEHRGSEASPALPGLKLSADQVALVYST	166
TACI 528	-----	43

FIG. 17B

BCMA	710	MLQAGQCSQNEYFDSLLHACIFCQLRCSNTPLTCQRYCNASVTNSVKG	54
BCMA	356	--LQAGQCSQNEYFDSLLHACIFCQLRCSNTPLTCQRYCNASVTNSVKG	53






FIG. 19A



1. Fc Control
2. Abatacept
3. 186 CTLA-4-Fc
4. CTLA4 186 - GSG4S - Fc - (G4S)4 - TACI 541
5. TACI 30-110 - Fc

FIG. 19B



6. TACI 13-118 - Fc
7. 406 BCMA-Fc
8. 381 BCMA -Fc
9. 411 BCMA -Fc
10. Naive

FIG. 20




FIG. 21




FIG. 22A




FIG. 22B




FIG. 22C





FIG. 22D



1. Fc Control

2. Abatacept

3. 186 CTLA-4-Fc

4. CTLA4 186 - GSG4S - Fc - (G4S)4 - TACI 541

5. TACI 30-110 - Fc
6. TACI 13-118 - Fc


7. 406 BCMA -Fc

8. 381 BCMA -Fc

9. 411 BCMA -Fc

10. Naïve

FIG. 23



- | | |
|---|---------------------|
| 1. Fc Control | 6. TACI 13-118 – Fc |
| 2. Abatacept | 7. 406 BCMA -Fc |
| 3. 186 CTLA-4-Fc | 8. 381 BCMA -Fc |
| 4. CTLA4 186 - GSG4S - Fc - (G4S)4 - TACI 541 | 9. 411 BCMA -Fc |
| 5. TACI 30-110 – Fc | 10. Naïve |

FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B




FIG. 26




FIG. 27




FIG. 28A




FIG. 28B




FIG. 28C





FIG. 29

